HALIFAX, Nova Scotia, May 25, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, today announced that IMV Chief Executive Officer Frederic Ors will present a corporate
update at the National Bank Financial
8th Annual Quebec Conference.
Mr. Ors’ presentation will occur Wednesday, May 30, 2018 at 2:00 p.m. ET in the Museum Room in the Shangri-La
Hotel in Toronto. A copy of the presentation will be available on IMV’s website: www.imv-inc.com
National Bank Financial Markets hosts a series of conferences and events each year to bring together business
leaders, decision-makers and subject-matter experts to explore strategies, trends and opportunities.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly
applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of
immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of
action that enables the reprogramming of immune cells in vivo, which are aimed at generating powerful new
synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell activating immunotherapy that combines the
utility of the platform with a target: survivin. IMV is currently conducting three Phase 2 studies with Incyte and Merck
assessing DPX-Survivac as a combination therapy in ovarian cancer and diffuse large B-cell lymphoma. Connect at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are
based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. IMV Inc. assumes no responsibility to update forward-looking statements in this
press release except as required by law.
Contacts for Immunovaccine:
MEDIA
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: info@imv-inc.com
Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E: patti.bank@westwicke.com
